Reta glucagon-like peptide-1 (GLP-1) receptor agonists provide a groundbreaking approach to diabetes management. These innovative therapies function by mimicking the natural actions of GLP-1, a hormone produced by the gut in response to food. By triggering GLP-1 receptors in the pancreas, these substances enhance insulin release and reduce glucagon

The burgeoning landscape of emerging treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a similar therapeutic goal – improving glycemic control and promoting significant weight reduction – they exhibit intriguing differences in thei